IL296517A - Methods of treating sars-cov-2 infections - Google Patents
Methods of treating sars-cov-2 infectionsInfo
- Publication number
- IL296517A IL296517A IL296517A IL29651722A IL296517A IL 296517 A IL296517 A IL 296517A IL 296517 A IL296517 A IL 296517A IL 29651722 A IL29651722 A IL 29651722A IL 296517 A IL296517 A IL 296517A
- Authority
- IL
- Israel
- Prior art keywords
- dantrolene
- administering
- subject
- host cell
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063008486P | 2020-04-10 | 2020-04-10 | |
| US202063062599P | 2020-08-07 | 2020-08-07 | |
| PCT/US2021/026302 WO2021207443A1 (en) | 2020-04-10 | 2021-04-08 | Methods of treating sars-cov-2 infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL296517A true IL296517A (en) | 2022-11-01 |
Family
ID=75787221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL296517A IL296517A (en) | 2020-04-10 | 2021-04-08 | Methods of treating sars-cov-2 infections |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12605364B2 (https=) |
| EP (1) | EP4132518B1 (https=) |
| JP (1) | JP2023521163A (https=) |
| KR (1) | KR20230002371A (https=) |
| CN (1) | CN115361947A (https=) |
| AU (1) | AU2021253866A1 (https=) |
| BR (1) | BR112022020193A2 (https=) |
| CA (1) | CA3174710A1 (https=) |
| IL (1) | IL296517A (https=) |
| MX (1) | MX2022012705A (https=) |
| WO (1) | WO2021207443A1 (https=) |
| ZA (1) | ZA202210474B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021254415A1 (en) * | 2020-04-10 | 2022-10-20 | Eagle Pharmaceuticals, Inc. | Methods of treating Severe Acute Respiratory Syndrome |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY201417A (en) * | 2017-10-20 | 2024-02-21 | Eagle Res Labs Limited | Dantrolene prodrugs and methods of their use |
| US11123328B2 (en) | 2017-11-14 | 2021-09-21 | University Health Network | Dantrolene and analogs thereof for the chronic treatment and prevention of dyssynchronous cardiac dysfunction |
| WO2019175761A1 (en) | 2018-03-12 | 2019-09-19 | Orbicular Pharmaceutical Technologies Private Limited | Ready to use dantrolene compositions |
| US12246028B2 (en) * | 2018-11-27 | 2025-03-11 | Eagle Research Labs Limited | Use of dantrolene and dantrolene prodrugs to treat radiation exposure |
| AU2021254415A1 (en) * | 2020-04-10 | 2022-10-20 | Eagle Pharmaceuticals, Inc. | Methods of treating Severe Acute Respiratory Syndrome |
-
2021
- 2021-04-08 US US17/995,602 patent/US12605364B2/en active Active
- 2021-04-08 BR BR112022020193A patent/BR112022020193A2/pt unknown
- 2021-04-08 EP EP21723473.1A patent/EP4132518B1/en active Active
- 2021-04-08 AU AU2021253866A patent/AU2021253866A1/en active Pending
- 2021-04-08 CN CN202180027309.8A patent/CN115361947A/zh active Pending
- 2021-04-08 CA CA3174710A patent/CA3174710A1/en active Pending
- 2021-04-08 KR KR1020227034976A patent/KR20230002371A/ko active Pending
- 2021-04-08 WO PCT/US2021/026302 patent/WO2021207443A1/en not_active Ceased
- 2021-04-08 MX MX2022012705A patent/MX2022012705A/es unknown
- 2021-04-08 IL IL296517A patent/IL296517A/en unknown
- 2021-04-08 JP JP2022561997A patent/JP2023521163A/ja active Pending
-
2022
- 2022-09-21 ZA ZA2022/10474A patent/ZA202210474B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN115361947A (zh) | 2022-11-18 |
| KR20230002371A (ko) | 2023-01-05 |
| US20230144719A1 (en) | 2023-05-11 |
| ZA202210474B (en) | 2025-12-17 |
| MX2022012705A (es) | 2022-11-07 |
| WO2021207443A1 (en) | 2021-10-14 |
| AU2021253866A1 (en) | 2022-10-20 |
| JP2023521163A (ja) | 2023-05-23 |
| EP4132518A1 (en) | 2023-02-15 |
| US12605364B2 (en) | 2026-04-21 |
| EP4132518C0 (en) | 2025-08-13 |
| CA3174710A1 (en) | 2021-10-14 |
| BR112022020193A2 (pt) | 2022-11-22 |
| EP4132518B1 (en) | 2025-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL296517A (en) | Methods of treating sars-cov-2 infections | |
| IL296518A (en) | Methods for treating acute respiratory syndrome | |
| US20230181509A1 (en) | The use of diffusion enhancing compounds for treatment of viral and bacterial induced respiratory disease | |
| WO2021188787A1 (en) | Method for treatment of coronavirus infection | |
| Khubchandani et al. | Emerging therapeutic options for COVID-19 | |
| Ortega et al. | Cefepime-induced encephalopathy in a high-risk patient with renal insufficiency and cirrhosis | |
| HK40083259B (en) | Dantrolene for use in methods of treating sars-cov-2 infections | |
| HK40083259A (en) | Dantrolene for use in methods of treating sars-cov-2 infections | |
| WO2021207445A1 (en) | Methods of treating coronavirus infections | |
| WO2021207446A1 (en) | Methods of treating viral infections | |
| SaaChai et al. | Anesthetic aspect of malaria disease: a brief review | |
| HK40090314A (zh) | 治疗严重急性呼吸综合征的方法 | |
| WO2025104696A1 (en) | Pharmaceutical composition comprising edaravone for use in reducing levels of il-6 and tnf-alpha inflammatory markers and reducing time to withdrawal of oxygen therapy in patients with infectious diseases | |
| US20250241978A1 (en) | Peptide for prevention or treatment of covid-19 | |
| Singh et al. | A REVIEW: HYDROXYCHLOROQUINE AND ITS COMBINATION THERAPY WITH ANTIVIRAL DRUG USED NOVEL COVID-19 VIRUS | |
| Бонцевич et al. | Experience in managing a patient with a complicated course of SARS-COV-2 infection: early pulmonary rehabilitation and prevention of pulmonary fibrosis (clinical case) | |
| Alfano et al. | Le Infezioni in Medicina, n. 1, 11-21, 2022 | |
| TW202102224A (zh) | 使用經取代之多環吡啶酮衍生物及其前藥於患有流感及嚴重流感病況之個體中治療流感 | |
| Aoki | Peramivir |